P
Peter M.A. Calverley
Researcher at University of Liverpool
Publications - 374
Citations - 42164
Peter M.A. Calverley is an academic researcher from University of Liverpool. The author has contributed to research in topics: COPD & Exacerbation. The author has an hindex of 80, co-authored 363 publications receiving 38558 citations. Previous affiliations of Peter M.A. Calverley include Aintree University Hospitals NHS Foundation Trust & Ghent University.
Papers
More filters
Journal ArticleDOI
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary.
TL;DR: List of participants (GOLD Scientific Committee): Nicholas Anthonisen, Winnipeg, Canada, William C. Bailey, Birmingham, US, Tim Clark, London, UK, Leonardo Fabbri, Modena, Italy, Yoshinosuke Fukuchi, Tokyo, Japan; Lawrence Grouse, Seattle, US; James C. Hogg, Vancouver, Canada; Dirkje S. Postma, Groningen, the Netherlands.
Journal ArticleDOI
Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper
Bartolome R. Celli,William MacNee,Alvar Agusti,Antonio Anzueto,B. Berg,A. S. Buist,Peter M.A. Calverley,Niels H. Chavannes,T. Dillard,Bonnie F. Fahy,Alan M. Fein,John E. Heffner,Suzanne C. Lareau,Paula Meek,Fernando J. Martinez,Walter T. McNicholas,Jean W M Muris,E. Austegard,Romain Pauwels,S. I. Rennard,Adriano G. Rossi,NM Siafakas,B. Tiep,Jørgen Vestbo,E. F. M. Wouters,Richard ZuWallack +25 more
TL;DR: The main goals of the updated document are to improve the quality of care provided to patients with COPD and to develop the project using a disease-oriented approach.
Journal ArticleDOI
Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease
John R. Hurst,Jørgen Vestbo,Jørgen Vestbo,Antonio Anzueto,Nicholas Locantore,Hana Müllerová,Ruth Tal-Singer,Bruce E. Miller,David A. Lomas,Alvar Agusti,William MacNee,Peter M.A. Calverley,Stephen I. Rennard,Emiel F.M. Wouters,Jadwiga A. Wedzicha +14 more
TL;DR: Although exacerbations become more frequent and more severe as COPD progresses, the rate at which they occur appears to reflect an independent susceptibility phenotype, which has implications for the targeting of exacerbation-prevention strategies across the spectrum of disease severity.
Journal ArticleDOI
An Official American Thoracic Society Statement: Update on the Mechanisms, Assessment, and Management of Dyspnea
Mark B. Parshall,Richard M. Schwartzstein,Lewis Adams,Robert B. Banzett,Harold L. Manning,Jean Bourbeau,Peter M.A. Calverley,Audrey Gift,Andrew Harver,Suzanne C. Lareau,Donald A. Mahler,Paula Meek,Denis E. O'Donnell +12 more
TL;DR: There is a critical need for interdisciplinary translational research to connect Dyspnea mechanisms with clinical treatment and to validate dyspnea measures as patient-reported outcomes for clinical trials.
Journal ArticleDOI
Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial.
Peter M.A. Calverley,Romain Pauwels,Jørgen Vestbo,Paul W. Jones,Neil B. Pride,Amund Gulsvik,Julie A. Anderson,Claire Maden +7 more
TL;DR: In this article, a randomized, double-blind, parallel-group, placebo-controlled study with inhaled long-acting β 2 agonists and corticosteroid combination treatment produces better control of symptoms and lung function, with no greater risk of side-effects than that with use of either component alone.